Life Sciences Tools & Services Stocks Technical Data -- Research on PerkinElmer, BG Medicine, Covance, and PAREXEL Intl. Editor Note: For more information about this release, please scroll to bottom.
LONDON, May 19, 2014 /PRNewswire/ --
On Friday, May 16, 2014, the NASDAQ Composite ended at 4,090.59, up 0.52%, the Dow Jones Industrial Average finished the day 0.27% higher at 16,491.31, and the S&P 500 closed at 1,877.86, up 0.37%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 671.93, up 0.35%, with the index also advancing 2.03% in the last one month. Investor-Edge has initiated coverage on the following equities: PerkinElmer Inc. (NYSE: PKI), BG Medicine Inc. (NASDAQ: BGMD), Covance Inc. (NYSE: CVD) and PAREXEL International Corporation (NASDAQ: PRXL). Free technical research on PKI, BGMD, CVD and PRXL can be downloaded upon signing up at:
On Friday, PerkinElmer Inc.'s stock recorded a trading volume of 0.86 million shares, lower than its three months average volume of 0.95 million shares. The stock ended the day at $43.38, which was 1.10% above its previous day's closing of $42.91, and registered an intraday range of $42.44 and $43.38. Shares of the company traded at a PE ratio of 25.91. PerkinElmer Inc.'s shares have lost 2.01% in the last one month and 0.66% in the previous three months. However, the stock has gained 5.21% since start of this year. The company's stock is trading above its 200-day moving average of $40.67, while the 200-day moving average is below PerkinElmer Inc.'s 50-day moving average of $44.41. Furthermore, shares of the company have a Relative Strength Index (RSI) of 47.24. Sign up today to read free research on PKI at:
BG Medicine Inc.'s stock finished the Friday's session 4.26% lower at $0.97. A total of 0.58 million shares were traded, which was below its three months average volume of 1.72 million shares. The stock moved between $0.96 and $1.04 during the session. BG Medicine Inc.'s stock has plummeted 23.86% in the previous three trading sessions, 23.25% in the last one month and 7.02% on YTD basis. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $1.43 is greater than its 200-day moving average of $1.07. BG Medicine Inc.'s stock has an RSI of 31.01. Sign up today to read free research on BGMD at:
On Friday, shares in Covance Inc. fluctuated between $83.80 and $85.27 before ending the session 0.74% higher at $84.67. Covance Inc.'s stock reported a trading volume of 0.48 million shares, close to its three months average volume of 0.55 million shares. Shares of the company traded at a PE ratio of 24.88. Although, Covance Inc.'s shares have gained 0.22% in the previous three trading sessions, it has declined 12.68% in the last one month and 3.85% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $95.98 and $90.76, respectively. Moreover, shares of the company have an RSI of 36.39. Sign up today to read free research on CVD at:
On Friday, shares in PAREXEL International Corp. gained 1.45%, to close the day at $46.91. The stock recorded a trading volume of 0.71 million shares, above its three months average volume of 0.59 million shares. The stock oscillated between $46.20 and $47.04 during the session. Over the last three trading sessions and since start of this year, PAREXEL International Corp.'s shares have gained 0.11% and 3.83%, respectively. However, the stock has lost 6.46% in the last one month. The stock is trading below its 50-day and 200-day moving averages. Further, the stock's 50-day moving average of $50.64 is greater than its 200-day moving average of $48.52. Additionally, the stock traded at a PE ratio of 22.71 and has an RSI of 46.98. Sign up today to read free research on PRXL at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.